Theranostics is a medical approach that combines the concepts of therapy and diagnostics. It uses targeted molecules that can first help identify disease through molecular imaging and can then be paired with a therapeutic radioactive agent to treat cells carrying the same biological target. Molecular imaging, meanwhile, provides information about cellular activity and biological processes rather than only showing the physical structure of organs. PET and SPECT are commonly used molecular imaging techniques.
Molecular imaging generally involves introducing a small amount of a radiotracer into the body. The tracer is designed to travel to particular tissues, receptors, or biological processes. A PET or SPECT scanner detects signals from the tracer and creates images that show where specific activity is occurring. This can help physicians evaluate disease location, extent, and biological characteristics.
Theranostics builds on this principle by connecting diagnosis with targeted treatment. A diagnostic radiopharmaceutical can identify whether a particular molecular target is present. If appropriate, a related therapeutic radiopharmaceutical can then deliver radiation to cells expressing that target.
Key aspects include:
Theranostics has become particularly important in oncology. Established applications include certain prostate cancers and neuroendocrine tumors, while researchers continue investigating additional uses. Radioactive iodine treatment for thyroid disease is an earlier example of targeted nuclear medicine therapy and helped establish principles that are central to modern theranostics.
Molecular imaging can also support diagnosis and treatment management by helping physicians assess disease progression, identify recurrence, evaluate treatment response, and understand the biological characteristics of tumors. Its ability to provide functional information can complement anatomical imaging methods such as CT and MRI.
Important areas of interest include:
Theranostics and molecular imaging are also subject to careful radiation safety practices. Nuclear medicine professionals select appropriate radiotracer amounts and follow established safety procedures. The suitability of a particular imaging test or radiopharmaceutical treatment depends on the individual patient, disease characteristics, medical history, and clinical guidance.
Overall, theranostics and molecular imaging represent an important direction in precision medicine. By connecting molecular information with targeted therapy, these technologies can help physicians better understand disease and make more informed treatment decisions. Continued research is expected to expand the number of molecular targets, imaging agents, and therapeutic applications available in clinical practice.